Clinical Trials Logo

Filter by:
NCT ID: NCT01283139 Completed - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

Start date: March 31, 2011
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).

NCT ID: NCT01282450 Completed - Clinical trials for Non-small Cell Lung Cancer

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)

Start date: May 2006
Phase: Phase 2
Study type: Interventional

In recent years, it has become clear, that also in non-small cell lung cancer (NSCLC), a group of patients with less than 5 distant metastases may experience long-term survival when treated radically to all macroscopic cancer sites. Thus has mostly been established for individuals with so-called solitary brain metastases and to a lesser extend in solitary adrenal gland metastases, but in other metastatic subgroups, the same may be applicable. In a prospective survey in the region of the Integral Cancercentre (IKL), we could identify on a yearly base 30 patients with NSCLC who could theoretically be amendable for radical treatment of all oligo-metastatic locations. We therefore want to perform a prospective study in which patients with less than 4 oligo-metastatic sites from a primary NSCLC will be treated radically with the aim to improve long-term survival. As many discussion points remain, even after thorough discussions with chest physicians, pulmonary surgeons and colleagues from diagnostic disciplines, we decided to go for a pragmatic approach, implying that all macroscopic disease sites should be treated radically, being defined as surgery with a R0 resection or in case of an unforeseen R1 resection, followed by radiotherapy, or radiotherapy to a biological equivalent of at least 60 Gy in 30 daily fractions. In the same patient, one metastatic site may be treated with surgery and another with radical radiotherapy. Systemic treatment was not made mandatory, because it was felt that it's role is unclear in patients with early stage local cancer and with oligo-metastatic disease.

NCT ID: NCT01282437 Completed - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC

NVALT11
Start date: January 2009
Phase: Phase 3
Study type: Interventional

For patients with stage III non-small cell lung cancer, which is radically treated, we will investigate whether prophylactic cranial irradiation (PCI) should become standard of care to prevent brain metastases.

NCT ID: NCT01281527 Completed - Schizophrenia Clinical Trials

Paliperidone Palmitate Flexible Dosing in Schizophrenia

PALMFlexS
Start date: November 2010
Phase: Phase 3
Study type: Interventional

This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.

NCT ID: NCT01281280 Completed - Epilepsy Clinical Trials

PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1

PuLsE 2
Start date: March 2011
Phase: N/A
Study type: Observational

This is a post-market, open observational long-term effectiveness follow-up study of participants with drug-resistant epilepsy with partial-onset seizures previously enrolled in a randomized controlled trial (PuLsE) comparing Best Medical Practice with or without adjunctive Vagus Nerve Stimulation Therapy.

NCT ID: NCT01281228 Completed - Obesity Clinical Trials

The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes

Braini-Ex
Start date: September 2011
Phase: N/A
Study type: Interventional

Glucagon-like peptide 1 (GLP-1) based therapies, such as exenatide, are already successfully employed in the treatment of Type 2 Diabetes (T2DM). Exenatide improves glycemic control and is associated with reduced food intake and body weight. The investigators hypothesize that it affects central reward and satiety circuits and that this may contribute to the weight loss.

NCT ID: NCT01281189 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Phase 3 Study of Dexpramipexole in ALS

EMPOWER
Start date: March 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).

NCT ID: NCT01279382 Completed - Clinical trials for Irritable Bowel Syndrome

Effect of Hypnotherapy in Irritable Bowel Syndrome (IBS)

Start date: January 2002
Phase: N/A
Study type: Interventional

In this trial, the effects of two psychological interventions - i.e. hypnotherapy and relaxation training - are compared with care as usual in IBS treatment. The investigators hypothesized that hypnotherapy is most effective in reducing complaints in IBS.

NCT ID: NCT01279317 Completed - Clinical trials for Type 2 Diabetes Mellitus

Vinegar Co-ingestion in Type 2 Diabetes

Start date: September 2010
Phase: N/A
Study type: Interventional

The main objective of this study is to assess the acute effect of co-ingested vinegar on postprandial plasma glucose levels in type 2 diabetes patients.

NCT ID: NCT01279304 Completed - Breast Cancer Clinical Trials

Radiotherapy After Primary Chemotherapy for Breastcancer

RAPCHEM
Start date: January 2011
Phase:
Study type: Observational

The primary aim of the study is to evaluate the 5 yr locoregional recurrence rate (LRR) in cT1-2cN0-1(cytology/histology and/or positive SN, excluding patients with > 3 pathologic axillary nodes on imaging) breast cancer patients, treated with neoadjuvant chemotherapy, breast surgery, and radiotherapy that is protocolized based on the pathology findings after chemotherapy and definitive surgery (ypTNM stage).